Omalizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Omalizumab |
| DrugBank ID | DB00043 |
| Brand Names (EU) | Xolair |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Allergic asthma Xolair is indicated in adults, adolescents and children (6 to <12 years of age). Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma. Adults and adolescents (12 years of age and older) Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung funct
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 100.00% | DL |
| 2 | atopic eczema | 99.97% | DL |
| 3 | obstructive lung disease | 99.97% | DL |
| 4 | allergic asthma | 99.97% | DL |
| 5 | dermatitis | 99.97% | DL |
| 6 | intrinsic asthma | 99.97% | DL |
| 7 | bronchial neoplasm (disease) | 99.95% | DL |
| 8 | acne keloid | 99.94% | DL |
| 9 | acrodermatitis chronica atrophicans | 99.93% | DL |
| 10 | hydroa vacciniforme, familial | 99.93% | DL |
| 11 | neonatal dermatomyositis | 99.93% | DL |
| 12 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 99.92% | DL |
| 13 | amyopathic dermatomyositis | 99.92% | DL |
| 14 | indolent plasma cell myeloma | 99.89% | DL |
| 15 | plasma cell myeloma | 99.86% | DL |
| 16 | chronic obstructive pulmonary disease | 99.81% | DL |
| 17 | compensatory emphysema | 99.80% | DL |
| 18 | interstitial emphysema | 99.80% | DL |
| 19 | hyperlucent lung | 99.80% | DL |
| 20 | tracheal stenosis | 99.77% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.